Trade names Xiidra Routes of
administration Eye drops Legal status US: ℞-only | AHFS/Drugs.com xiidra ATC code none Synonyms SAR-1118 | |
 | ||
Lifitegrast (trade name Xiidra) is a drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It is applied in the form of eye drops.
Contents
Adverse effects
Common side effects in clinical trials were eye irritation, discomfort, blurred vision, and dysgeusia (a distortion of the sense of taste).
Mechanism of action
Lifitegrast inhibits an integrin, lymphocyte function-associated antigen 1 (LFA-1), from binding to intercellular adhesion molecule 1 (ICAM-1). This mechanism down-regulates inflammation mediated by T lymphocytes.
History
Lifitegrast was initially designed and developed by SARcode Bioscience which was acquired by Shire in 2013, who submitted a new drug application to the US Food and Drug Administration (FDA) in March 2015. The FDA granted Shire a priority review a month later, and requested additional clinical data, which were supplied in January 2016. The drug was finally approved on 11 July 2016.